블로그

• Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer In the phase III DESTINY-Breast09 trial, first-line treatment with the antibody-drug conjugate fam-trastuzumab blog.naver.com · 2025.06.27